nti glucocorticoid receptor transcripts lack sequences encoding the amino-terminal transcriptional modulatory domain

The origin and functions of multiple human glucocorticoid receptor isoforms

Glucocorticoid hormones are necessary for life and are essential in all aspects of human health and disease. The actions of glucocorticoids are mediated by the glucocorticoid receptor (GR), which binds glucocorticoid hormones and regulates gene expression, cell signaling, and homeostasis. Decades of research have focused on the mechanisms of action of one isoform of GR, GRa. However, in recent years, increasing numbers of human GR (hGR) isoforms have been reported. Evidence obtained from this and other laboratories indicates that multiple hGR isoforms are generated from one single hGR gene via mutations and/or polymorphisms, transcript alternative splicing, and alternative translation initiation. Each hGR protein, in turn, is subject to a variety of posttranslational modifications, and the nature and degree of posttranslational modification affect receptor function. We summarize here the processes that generate and modify various hGR isoforms with a focus on those that impact the ability of hGR to regulate target genes. We speculate that unique receptor compositions and relative receptor proportions within a cell determine the specific response to glucocorticoids. Unchecked expression of some isoforms, for example hGRbeta, has been implicated in various diseases.

Correlation of membrane glucocorticoid receptor levels with glucocorticoid-induced apoptotic competence using mutant leukemic and lymphoma cells lines

We have studied the presence and functional implications of membrane glucocorticoid receptor (mGR) in several wild type (WT) and mutant mouse lymphoid cell lines (nuclear transfer decrease, NT(-); nuclear transfer increase, NT(i); and receptorless, R(-)). Direct fluorescent antibody staining revealed large aggregates of mGR-specific fluorescing antigens in the plasma membrane of the WT and mGR-enriched (mGR(++)) S-49 cells. While R(-) cells totally lacked mGR, this receptor level was low in NT(-) and NT(i) groups. FACS analysis corroborated these results, showing a approximately 4-10-fold difference between the highest mGR levels (mGR(++)) and the R(-) and NT(i) cells. Membrane extracts were analyzed for mGR by immunoblotting. Multiple receptor forms, ranging in M(r) from 94,000 to > 200,000, were observed in the WT cells, while only smaller peptides (85,000-94,000) were found in NT(-) cells. No detectable immunoreactive bands were identified in either membrane or cytosol immunoprecipitates of NT(i) and R(-) cell groups. Within 48 h post dexamethasone exposure > 98% of WT and mGR(++) S-49 cells underwent apoptosis, compared to 0-30% in the mutant cells, albeit the total receptor number is two to three times higher in NT(i) compared to WT. These results suggest a better correlation between the quantity and quality of mGRs (rather than total cellular GRs) and the ability of glucocorticoids (GCs) to lyse lymphoid cells.

Aberrant HS1 molecule in a patient with systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the activation of autoreactive B lymphocytes, which are supposed to carry aberrant signal transduction after the stimulation of B-cell receptor (BCR). To investigate abnormalities in BCR-mediated signaling pathway in lupus B lymphocytes, we analyzed HS1, a molecule downstream of BCR, in 80 Japanese SLE patients. We identified 37 amino acid deletion of HS1 in a 25-year-old female patient, and the aberrant HS1 lacked a part of a functional motif. Analysis of genomic DNA revealed that the aberrant HS1 was caused by exon skipping. Family study showed that the patient as well as her father and sister are heterozygous for the abnormality. WEHI-231 cell, a mouse B cell line, transfected with the aberrant HS1 displayed a significantly increased cell death upon cross-linking of BCR. Additionally, peripheral B lymphocytes from the patient exerted increased apoptosis after BCR stimulation compared to those from control SLE patients. These data suggest that the aberrant HS1 molecule may transmit an accelerated signal after BCR stimulation and may play a role in the activation of autoreactive B lymphocytes.

Dysfunctional glucocorticoid receptor with a single point mutation ablates the CCAAT/enhancer binding protein-dependent growth suppression response in a steroid-resistant rat hepatoma cell variant

We used glucocorticoid-resistant and -sensitive hepatoma cell variants to characterize the mechanism of hepatoma cell resistance to the growth inhibitory effects of glucocorticoids. BDS1 hepatoma cells express transcriptionally active glucocorticoid receptors and undergo a stringent G1 cell cycle arrest in response to glucocorticoids that is dependent on the induced expression of the CCAAT/enhancer binding protein alpha (C/EBPalpha) transcription factor. In contrast, EDR1 hepatoma cells, which express normal levels of glucocorticoid receptors, fail to growth arrest or express C/EBPalpha when treated with glucocorticoids. Ectopic expression of wild-type rat glucocorticoid receptors into EDR1 cells restored the growth suppression response, suggesting a defect in the EDR1 receptor. DNA sequence analysis revealed a single point mutation causing a cysteine-to-tyrosine substitution at amino acid position 457 (C457Y-GR) in the zinc finger region of the glucocorticoid receptor that mediates both receptor-DNA and receptor-protein interactions. Glucocorticoid activation of the alpha1-acid glycoprotein (AGP) promoter, a liver acute-phase response gene, requires receptor-DNA binding as well as an interaction with C/EBPalpha. In contrast to the wild-type glucocorticoid receptor, ectopic expression of C/EBPalpha in EDR1 cells, or coexpression of C/EBPalpha along with the C457Y-GR into receptor-deficient EDR3 cells was required to partially restore glucocorticoid responsiveness of the AGP promoter by the EDR1 glucocorticoid receptor. Constitutive expression of the wild-type glucocorticoid receptor, but not the C457Y-GR mutant, was sufficient to restore the glucocorticoid growth suppression response to receptor-deficient EDR3 cells. Thus, we have identified a glucocorticoid-resistant hepatoma cell variant with a single point mutation in the zinc finger region of the glucocorticoid receptor gene that ablates the glucocorticoid growth suppression response and attenuates transcriptional activation of the AGP promoter.

The DNA-binding and tau2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal

Using an ATP-depletion paradigm to augment glucocorticoid receptor (GR) binding to the nuclear matrix, we have identified a minimal segment of the receptor that constitutes a nuclear matrix targeting signal (NMTS). While previous studies implicated a role for the receptor's DNA-binding domain in nuclear matrix targeting, we show here that this domain of rat GR is necessary, but not sufficient, for matrix targeting. A minimal NMTS can be generated by linking the rat GR DNA-binding domain to either its tau2 transactivation domain in its natural context, or a heterologous transactivation domain derived from the Herpes simplex virus VP16 protein. The transactivation and nuclear matrix-targeting activities of tau2 are separable, as transactivation mutants were identified that either inhibited or had no apparent effect on matrix targeting of tau2. A functional interaction between the NMTS of rat GR and the RNA-binding nuclear matrix protein hnRNP U was revealed in cotransfection experiments in which hnRNP U overexpression was found to interfere with the transactivation activity of GR derivatives that possess nuclear matrix-binding capacity. We have therefore ascribed a novel function to a steroid hormone transactivation domain that could be an important component of the mechanism used by steroid hormone receptors to regulate genes in their native configuration within the nucleus.

Position 16 of the steroid nucleus modulates glucocorticoid-induced apoptosis at the transcriptional level in murine T-lymphocytes

Synthetic glucocorticoids (GCs), which possess a different radical substituted in position 16 of the steroid nucleus structure, display various antiproliferative activities on activated lymphoid cells. We analysed this structure-function relationship between dexamethasone (DEX; methyl group in position 16 alpha) and beta-methasone (BM; methyl group in position 16 beta) with regard to two important aspects of GC activity, namely the activation of transcription and induction of apoptosis in IL-2-dependent murine lymphoid cells. DEX induced a higher percentage of apoptotic viable cells compared to BM. This structure-activity relationship was not related to differences in cytosolic glucocorticoid receptor (GR) affinity or kinetics of apoptosis. However, DEX was more efficient than BM in inducing transcriptional activation of an MMTV-CAT plasmid in transiently transfected CTLL-2 cells. In addition, DEX was more potent in inhibiting AP-1 DNA-binding activity compared to BM. These results suggest that the configuration in position 16 may influence the potency of GCs to induce apoptosis in lymphoid cells, mainly by modulating GR-induced transcription.

Differential binding of mutant glucocorticoid receptors to the glucocorticoid response element of the tyrosine aminotransferase gene

Glucocorticoid receptors (GCRs) in sublines of the mouse P1798 lymphosarcoma that are sensitive (S) or resistant (R) to glucocorticoid-induced cell lysis were examined for their ability to bind to a single glucocorticoid responsive element (GRE). Mobility shift assays detected two specific complexes that were identical in both S and R cellular extracts. Antibodies against the GCR N-terminus supershifted complexes, suggesting that the 97 kDa wild-type GCR (WT-GCR) in S cells, and the variant, 97 kDa non-steroid-binding GCR (NSB-GCR) in R cells were components of both complexes. Sephacryl S300 gel filtration column fractions containing the WT-GCR and NSB-GCR formed complexes with the GRE, while fractions containing a second GCR variant in R cells, the 45 kDa steroid-binding truncated GCR (TR-GCR), did not. Southwestern blotting detected a GRE-binding, 97 kDa protein band in both S and R extracts. A 45 kDa band was not detected. UV crosslinking of protein to DNA revealed protein in the range of 92-120 kDa crosslinked to the GRE in both S and R extracts. No crosslinking was detected at 45 kDa. Strong interaction of the NSB-GCR with GREs and lack of binding of the TR-GCR to single GREs illustrate a complex receptor system in the P1798 lymphosarcoma.

Identification and localization of steroid-binding and nonsteroid-binding forms of the glucocorticoid receptor in the mouse P1798 lymphosarcoma

Glucocorticoid receptors (GCRs) were characterized in sublines of the mouse P1798 lymphosarcoma that are sensitive (S) or resistant (R) to glucocorticoid-mediated apoptosis. Previous work had identified two steroid-binding GCRs in S and R cells: a 97 kDa wild-type GCR in S cells (WT-GCR), and a 45 kDa truncated GCR in R cells (TR-GCR). A third GCR, a 97 kDa nonsteroid-binding GCR (NSB-GCR), was also identified in R cells. Using subcellular fractionation and Western blotting, we now show that in contrast to the WT-GCR which is localized in both the cytoplasm and nucleus of S cells, the NSB-GCR is localized predominantly in R cell nuclei. Moreover, gel filtration chromatography revealed that treatment with 400 mM NaCl and heat did not significantly alter the Stokes radius of the NSB-GCR suggesting that this receptor is not present in a heterooligomeric complex with other proteins. The TR-GCR was localized predominantly in the soluble cytoplasmic fraction but also in the crude membrane fractions of R cell nuclei, suggesting that this receptor is tightly associated with nuclear structures. It was not detected in the soluble nuclear fraction. Unexpectedly, a 45 kDa nonsteroid-binding immunoreactive protein was detected in crude membrane fractions of S cells. These studies describe a complex GCR system in the P1798 lymphosarcoma that necessitates a further consideration of glucocorticoid signaling in S and R cells.

Charge heterogeneity in wildtype and variant glucocorticoid receptors

Two-dimensional electrophoresis was used to examine charge heterogeneity in glucocorticoid receptors (GCRs) from sublines of the thymic-derived, mouse P1798 lymphosarcoma which were sensitive (S) or resistant (R) to glucocorticoid-mediated apoptosis. Previous work had identified the 97 kDa wildtype GCR (WT-GCR) in S cells and two variant GCRs in R cells: a 45 kDa, steroid-binding truncated GCR (TR-GCR), and a 97 kDa non steroid-binding GCR (NSB-GCR). Using denaturing isoelectric focusing, we now show that S cells as well as adult mouse thymus gland also express the NSB-GCR at pI 5.6 in addition to the WT-GCR which resolves between pH 5.9-7.1. Thus, the NSB-GCR is detected in steroid-sensitive cells and is not unique to R cells. Separation of receptors by native isoelectric focusing suggested that the TR-GCR in R cells resolved at a single, high pI (8.1) relative to the WT-GCR which resolved in a broad range (pI 5.8-8.0). The high pI of the TR-GCR may alter its functional activity thereby contributing to the resistance phenotype.

Molecular genetic analysis of glucocorticoid signaling during mouse development

Glucocorticoids are important in a number of developmental processes in mammals around birth. The pathway of gluconeogenesis is activated in liver shortly after birth due to the combined effects of glucocorticoids and glucagon. We have defined the essential cis-regulatory elements directing hormone-dependent liver-specific expression of the gene for tyrosine aminotransferase, a key gluconeogenic enzyme. The hormone response elements synergize with cell-type specific elements. In the case of glucocorticoids, the glucocorticoid-dependent enhancer is composed of the glucocorticoid response element and binding sites for liver cell-enriched transcription factors, in particular hepatocyte nuclear factor-3. The dependence of the respective enhancer motifs on each other restricts the hormonal activation of the tyrosine aminotransferase gene in liver in response to a hormonal signal. To further understand the role of glucocorticoid signaling via the type II glucocorticoid receptor (GR) in the perinatal period and earlier during development, we have studied the expression of the mouse GR gene. Expression of the gene is controlled by at least three promoters, one of which is only active in T-lymphocytes. Expression of GR mRNA has been detected as early as day 9.5 of mouse development. To specifically address the role of glucocorticoid signaling via the GR during development, we have disrupted the GR gene by homologous recombination in mouse embryonic stem cells. The majority of GR mutants die shortly after birth and analysis so far has revealed defects in lung, liver, and adrenal function.

Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies

Glucocorticoids are highly effective in inducing the cytolysis of cells of lymphocytic origin. This property has resulted in their incorporation into chemotherapy regimens used in the treatment of hematologic malignancies. Studies at the molecular and cellular levels have demonstrated that the hormone-induced cytolytic response is mediated through a highly specific cytoplasmic glucocorticoid receptor (GR). The GR has been cloned and sequenced and found to be organized into a discrete series of domains which mediate the receptor functions of hormone binding, nuclear translocation, DNA binding and transcriptional modulation. Thus, the binding of glucocorticoids by the GR induces a series of cellular events which result in the activation or repression of a network of glucocorticoid responsive genes and produces a specific cellular response. Prolonged exposure to glucocorticoids ultimately causes resistance to develop; thereby limiting the usefulness of this class of drugs. Studies addressing the mechanism of resistance have shown that the GR is the primary target of genetic alterations that lead to resistance to cytolysis. Using mouse and human cell lines as model systems, it has been shown that the vast majority of glucocorticoid resistant mutants express low levels or altered forms of the GR. Similarly, in vivo studies on patients have suggested that low GR levels are associated with a poor response to glucocorticoid based therapies. Recently, aberrant GR isolated from a patient with multiple myeloma resistant to glucocorticoids were found to harbor deletions in their hormone binding domains. Sequencing of the receptors suggested that each arose as a result of alternate splicing events. In both cases, the latter event produces a receptor unable to bind hormone leading to the speculation that alternate splicing may serve as a mechanism by which a cell evades the effects of glucocorticoids. The therapeutic implications for patients expressing aberrant receptors is discussed.

Heterogeneity in the 5' untranslated region of the rat glucocorticoid receptor mRNA

We have cloned several novel sequences upstream from the first coding exon of the rat glucocorticoid receptor (GR) mRNA using PCR. Analysis of these sequences in RNase protection assays showed that one of the cloned sequences represents the major GR 5' non-coding exon which is expressed in all tissues studied, both at different stages of development and under different hormonal conditions. This major exon is homologous to the human GR 5' untranslated region (UTR). Three other sequences were cloned, but could not be detected in the RNase protection assay, suggesting that they are only minor transcripts, at least under the varying conditions of GR expression studied. One of these sequences is identical to a previously described rat GR cDNA sequence, while another was shown to be contiguous with the rat genomic DNA sequence.

The structure of glucocorticoid receptors

The glucocorticoid receptor of mouse thymic lymphoma cells was investigated. The receptor-hormone complex in cytosolic extracts has a Stokes' radius of 82 A and Mw approximately 330 kDa. In the presence of salt at high concentrations, however, the receptor-complex has a Stokes' radius of 60 A and Mw approximately 120 kDa. This receptor form is able to interact with DNA. Chemical cross-linking was used to stabilize the high molecular weight receptor structure against subunit dissociation and this was found to prevent receptor activation to DNA binding. The affinity labeled receptor was submitted to progressive cross-linking and the intermediate cross-linked forms were analyzed. This led to the conclusion that the high molecular weight receptor structure is a hetero-tetramer consisting of one receptor polypeptide of approximately 100 kDa, two molecules of the 90 kDa heat shock protein hsp90 and an additional protein subunit. The latter was unequivocally identified by immunochemical techniques as the 59 kDa protein p59. The 70 kDa heat shock protein was found not to be a bona fide receptor component but was a contaminant of our immunopurification procedure. Cross-linking studies also showed that the receptor exists in the high molecular weight form in intact cells and in the absence of hormone.

Elevated glutathione S-transferase gene expression is an early event during steroid-induced lymphocyte apoptosis

Based on the finding that glutathione S-transferase Yb1 (GST) gene expression is elevated in the regressing prostate of androgen-ablated rats, we analyzed GST transcript levels during steroid-induced lymphocyte cell death. It was found that GST gene expression was induced in steroid-sensitive cells within 4 hr of dexamethasone treatment, required functional glucocorticoid receptor, and was dose-dependent with regard to hormone. GST expression was not induced in an apoptosis-defective variant that contained normal levels of functional receptor, indicating that GST up-regulation was the result of secondary events that occur during steroid-mediated apoptosis. Using the calcium ionophore A23817 to induce lymphocyte cell death, GST RNA levels were increased in both steroid-sensitive and steroid-resistant cell lines, supporting the conclusion that elevated GST expression was the result of cellular processes associated with apoptosis, rather than a direct consequence of steroid-mediated transcriptional control. The cells were also treated with dibutyryl cAMP to cause cell death; however, this mode of killing did not result in GST up-regulation. Taken together, these results suggest that GST induction in dexamethasone-treated T-lymphocytes occurs early in the steroid-regulated apoptotic pathway and that this may be a marker of calcium-stimulated cell death. Based on the known function of GST as an antioxidant defense enzyme and its transcriptional regulation by reactive oxygen intermediates, we propose that the gene product of a primary GR target gene(s) directly or indirectly effects the redox state of the cell. Thus activation of GST gene expression in apoptotic lymphocytes is likely a indicator of oxidative stress, rather than a required step in the pathway.

Monoclonal antipeptide antibodies to the glucocorticoid receptor

The generation of monoclonal antibodies to synthetic peptides of the glucocorticoid receptor is described. Two antibodies to sequences from the DNA binding region are IgMs. Two other antibodies to sequences in the steroid binding region and the C-terminus belong to the IgG class. The specificity of the IgG binding to the receptor in an ELISA assay is demonstrated by competition with the relevant peptides. Both IgGs are able to recognize the receptor in Western blots, but do not form stable complexes in sucrose gradients. Steroid binding to the receptor is not influenced by preincubation with antibodies. This indicates that denaturation or distortion of the receptor is necessary for the accessibility of these antibodies to their epitopes. Both antibodies can be used to stain the glucocorticoid receptor in neoplastic cells of patients suffering from chronic lymphatic leukemia.

Glucocorticoids in malignant lymphoid cells: gene regulation and the minimum receptor fragment for lysis

We have examined clones of human malignant lymphoid cells for markers that correlate with glucocorticoid-mediated cell lysis. In glucocorticoid-sensitive clones of CEM, a human T-cell lymphoblastic leukemia line, two genes correlate with glucocorticoid-induced cell lysis. The glucocorticoid receptor (GR) itself is induced by standard glucocorticoids in sensitive clones and not in insensitive clones. The phenylpyrazolo-glucocorticoid cortivazol (CVZ) is capable of lysing several clones resistant to high concentrations of standard potent glucocorticoids. When these clones were tested for cortivazol responses, they were not only lysed by cortivazol but also showed induction of GR mRNA. Thus receptor induction appears to correlate with the lysis function of receptor in these cells. To determine what parts of the GR are required for lysis, we have mapped this function by transfecting and expressing GR and GR fragment genes in a GR-deficient CEM clone. Our results indicate that none of the known trans-activation regions of the GR are required. Removal of the steroid binding domain gives a fragment that is fully constitutive. Only one and one-half "Zn fingers" of the DNA binding region are required. We also find in CEM cells rapid suppression of the c-myc protooncogene, preceding growth arrest and cell lysis by glucocorticoids. This occurs only in clones possessing both intact receptors and lysis function. Thus the simple presence of GR alone is not sufficient to guarantee c-myc down-regulation. Introduction into the cells of c-myc driven by a promoter that does not permit suppression by glucocorticoids confers resistance to steroids. Furthermore, suppression of c-myc by antisense oligonucleotides also kills the cells. Therefore, c-myc appears to be a pivotal gene related both to ability of steroid to kill and to cell viability.

Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma

A clonal mouse prostate carcinoma was established by the introduction of the ras and myc oncogenes via the recombinant retrovirus Zipras/myc 9 using a mouse prostate reconstitution model system. A single-cell suspension derived from an early passage ras+myc-induced carcinoma was inoculated into the flanks of intact or castrated adult male C57BL/6 mice, and tumors were harvested 3 wk postinoculation for northern and Southern blotting. Tumor volume analysis showed that this carcinoma was not dependent on testicular androgens for growth. Southern blot analysis of virus-cell DNA junction fragments revealed that tumor cell populations recovered from both intact and castrated mice were progeny of the same virus-infected cell. Northern blotting showed that mRNA levels for the four growth-related genes transforming growth factor-beta 1 (TGF-beta 1), transforming growth factor-beta 3 (TGF-beta 3), tissue-type plasminogen activator (tPA), and c-myc were significantly elevated in clonal mouse prostate carcinomas grown in castrated hosts. In contrast, androgen receptor mRNA levels were significantly reduced under the same conditions. The response of TGF-beta 1, tPA, and c-myc mRNA levels in the carcinomas grown in castrated hosts was similar to that shown previously in normal rat ventral prostate. However, unlike normal rat ventral prostate after castration, increased numbers of apoptotic cells were not seen in the castrated group relative to the intact group at the time of analysis, indicating that the altered gene expression was not associated with cell death. In addition, testosterone-repressed prostate mRNA number 2 levels, shown previously to be elevated after castration in normal rat ventral prostate, were not increased in the androgen-deprived clonal mouse prostate carcinomas. Therefore, this early passage clonal ras+myc-induced prostate carcinoma demonstrates unique patterns of expression for a set of growth-related genes in an androgen-deprived environment.

New site-directed polyclonal antibody maps N-terminus of occluded region of the non-transformed glucocorticoid receptor oligomer to within BUGR epitope

Using a 17-mer synthetic peptide for immunization, a polyclonal antibody (WS933) directed against amino acid residues 395-411 of the mouse glucocorticoid receptor (GCR) has been raised and used to probe the significance of this region in forming the receptor oligomer and to localize the truncation site of the mutant GCR of the P1798 lymphosarcoma. This region of the receptor, which encompasses the BUGR epitope, is amino-terminal of and immediately adjacent to the DNA-binding domain. The polyclonal antibody WS933 reacted with both native and denatured forms of the wild-type mouse GCR as judged by its ability to shift the transformed receptor peak on Sephacryl S300 columns, to immunoadsorb the receptor to protein A Sepharose, and by immunoblot analysis where it identified the 98 kDa receptor protein in the cortisol-sensitive line of the P1798 mouse lymphosarcoma. WS933 also reacted with rat and rabbit GCR, but not human GCR. These characteristics were shared by the BUGR-2 monoclonal antibody. Unexpectedly, there were two highly significant differences between WS933 and BUGR-2. The first was the ability of WS933 to bind to the mutant 45 kDa GCR of the cortisol-resistant P1798 lymphosarcoma as judged by its capability of shifting the receptor peak on Sephacryl S300 columns. BUGR-2, in contrast, was unable to shift this mutant receptor peak. Secondly, WS933 was unable to react with the non-DNA-binding form of the wild-type (or mutant) GCR, whereas BUGR-2 could react with the non-DNA-binding form of the wild-type GCR. The first observation suggests that the truncation site of the mutant receptor may lie within a portion of the BUGR domain. Additionally, the second observation implies that at least part of the region lying within amino acid residues 395-411 of the mouse GCR is occluded in the receptor oligomer and that this site only becomes available upon transformation of the GCR to the DNA-binding form. This data provides the first mapping of the amino-terminus of the occluded region of the non-transformed receptor, and suggests that WS933 will be a useful probe for characterizing mutant as well as wild type glucocorticoid receptors.

The mechanism for glucocorticoid-resistance in a rat hepatoma cell variant that contains functional glucocorticoid receptor

The mechanism of glucocorticoid resistance has been studied in a rat hepatoma cell variant (6.10.2), which contains low levels of glucocorticoid receptor (GR). These cells seem to have lost all the glucocorticoid-induced transcriptional responses as measured by the lack of induction of expression of stably integrated mouse mammary tumor virus (MMTV) and the endogenous gene tyrosine aminotransferase (TAT), as well as the transcriptional suppression of GR gene expression. Physico-chemical characterization of the GR in the glucocorticoid resistant 6.10.2 cells revealed that the receptor is indistinguishable from the wild-type receptor with regard to size, hormone- and DNA-binding. The levels of the receptor mRNA and the total immunoreactive protein found in 6.10.2 cells were about 20% of those found in wild-type cells. Further analysis of 6.10.2 cells demonstrated that the receptor was indeed biologically functional. Treatment of 6.10.2 cells with 8-bromo-cAMP, which induced the endogenous GR level two-fold, restored responsiveness to glucocorticoids. Secondly, pretreatment of the cells with cycloheximide also led to reacquisition of cellular responsiveness to glucocorticoids. We propose that there exists a "threshold" level of GR, which is required for responsiveness and that under normal culture conditions, the level of GR in 6.10.2 cells is below this threshold. Glucocorticoid responsiveness can be restored by raising the GR level above the threshold with 8-bromo-cAMP or, alternatively, by removing the threshold barrier (repressor protein) with cycloheximide. Finally, the existence of such a repressor protein for MMTV induction was shown by in vivo titration with an isolated negative cis-element from the MMTV promoter.

Regulation of glucocorticoid receptor expression

A limiting factor determining the sensitivity of a cell to glucocorticoid hormones is the intracellular concentration of the glucocorticoid receptor (GR) protein. By regulating the expression of GR the cell is able to adapt to both changes in its hormone environment and to the varying requirements for biological response. Studies on the regulation of GR expression have shown this to be a complex process which involves both transcriptional and posttranscriptional mechanisms. Although GR is more or less constitutively expressed in most tissues its concentration varies under different physiological conditions. GR expression is regulated by a number of different agents including factors which act through a second messenger pathway. This allows the cell to control glucocorticoid regulated gene expression through a complex but integrated hormonal network. Here we summarize our studies on GR regulation with emphasis on: i), GR autoregulation; ii), the effect of cAMP on GR expression, and iii), GR expression during fetal rat lung development.